EMAIL THIS PAGE TO A FRIEND

Journal of cardiovascular pharmacology

β-Blockers promote angiogenesis in the mouse aortic ring assay.


PMID 24621648

Abstract

Recent results indicate that the reduction of β-adrenergic signaling impairs angiogenesis under ischemic conditions. Because angiogenesis may occur in the absence of ischemia, it remains to be determined whether and how β-adrenergic signaling regulates angiogenesis, which develops under normoxic conditions. The effect of β-adrenergic ligands on angiogenesis was investigated using 3-dimensional cultures of mouse aortic rings embedded in collagen type I, in which luminized microvessels develop in response to vascular endothelial growth factor (VEGF). Under normoxic conditions, both isoproterenol, a β-adrenergic receptor (β-AR) agonist, and forskolin, an adenylate cyclase activator, were unable to influence aortic microvessel sprouting. On the contrary, treatment with propranolol, a β-AR antagonist, caused an approximately 70% increase in VEGF-mediated microvessel sprouting. This effect was abolished in rings from both double β-AR and β1-AR knockout mice, but not in rings from β2-AR knockout mice. Significant increases in microvessel sprouting were also observed when mouse aortic rings from C57BL/6 mice were treated with the β1-AR-selective antagonists metoprolol and bisoprolol or with the β2-AR-selective antagonist ICI 118,551. Conversely, carvedilol, a nonselective β-AR antagonist, was unable to affect aortic sprouting. These findings suggest that some β-blockers display proangiogenic activity through a mechanism that is independent of their ability to antagonize catecholamine action. The present results also identify a new function for β-AR signaling as a facilitator for VEGF-mediated angiogenesis and have implications for understanding the mechanisms that regulate angiogenic responses under normoxic conditions.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M5391
(±)-Metoprolol (+)-tartrate salt, ≥98% (titration), powder
C30H50N2O6 · C4H6O6
80337
(±)-Metoprolol (+)-tartrate salt, analytical standard
C30H50N2O6 · C4H6O6
P0884
(±)-Propranolol hydrochloride, ≥99% (TLC), powder
C16H21NO2 · HCl
40543
(±)-Propranolol hydrochloride, analytical reference material
C16H21NO2 · HCl
50787
Bisoprolol, analytical standard
C18H31NO4
C3993
Carvedilol, ≥98% (HPLC), solid
C24H26N2O4
1096622
Carvedilol, United States Pharmacopeia (USP) Reference Standard
C24H26N2O4
PHR1265
Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material
C24H26N2O4
Y0001427
Carvedilol, European Pharmacopoeia (EP) Reference Standard
C24H26N2O4
Y0001426
Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard
C24H26N2O4
M1830000
Metoprolol tartrate, European Pharmacopoeia (EP) Reference Standard
C30H50N2O6 · C4H6O6
1441301
Metoprolol tartrate, United States Pharmacopeia (USP) Reference Standard
C30H50N2O6 · C4H6O6
PHR1076
Metoprolol Tartrate, Pharmaceutical Secondary Standard; Certified Reference Material
C30H50N2O6 · C4H6O6
1576005
Propranolol hydrochloride, United States Pharmacopeia (USP) Reference Standard
C16H21NO2 · HCl
P3500000
Propranolol hydrochloride, European Pharmacopoeia (EP) Reference Standard
C16H21NO2 · HCl
PHR1308
Propranolol hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
C16H21NO2 · HCl
P3600000
Propranolol hydrochloride for performance test, European Pharmacopoeia (EP) Reference Standard
C16H21NO2 · HCl